Prospective clinical study of melatonin combined with radiofrequency ablation in the treatment of early lung cancer

Efficacy and safety of melatonin combined with radiofrequency ablation in the treatment of early lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042695

Enrollment

Unknown

Registered

2021-01-26

Start date

2018-01-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early lung cancer

Interventions

RFA+MLT:RFA and Melatonin

Surgery:Surgery

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Aged 18-85 years; 2. Suspected and pathologically confirmed as early lung cancer with multiple pulmonary nodules; 3. No mediastinal lymph node enlargement or distant metastasis; 4. No systemic anti-tumor therapy was received in the past; 5. The function of main organs is normal.

Exclusion criteria

Exclusion criteria: 1. Participated in other clinical trials within 3 months before enrollment; 2. With contraindications of radiofrequency ablation or surgery and unable to complete the treatment; 3. Combined with other organ tumors; 4. With long-term oral hormone or autoimmune diseases; 5. Various hemorrhagic diseases, acute infectious diseases, fever and pregnancy; 6. Recovery period after cardiac surgery or stent implantation.

Design outcomes

Secondary

Measure	Time frame
Adverse events;Lung function;	—

Primary

Measure	Time frame
Disease-free survival;	—

Countries

China

Contacts

Public ContactLihong Fan

Shanghai 10th People's Hospital

fanlih@aliyun.com+86 18001763288

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026